86 related articles for article (PubMed ID: 2112756)
21. [Conditions for obtaining hemostatic preparations from donor plasma].
Kunakova NV; Diakonova SF; Rusanov VM; Rudnitskaia MZ
Gematol Transfuziol; 1989 Oct; 34(10):40-2. PubMed ID: 2515092
[No Abstract] [Full Text] [Related]
22. Recombinant factor VIII in hemophilia A: the Canadian experience.
Blanchette VS
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
[TBL] [Abstract][Full Text] [Related]
23. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis.
Morfini M; Lee M; Messori A
Thromb Haemost; 1991 Sep; 66(3):384-6. PubMed ID: 1746011
[No Abstract] [Full Text] [Related]
24. A quantitative two-stage assay for factor IX (Christmas factor) using plasma from dogs with Christmas disease.
Aronson DL; Dodds WJ; Mustafa AJ
Thromb Diath Haemorrh; 1972 Jul; 27(3):529-34. PubMed ID: 4662614
[No Abstract] [Full Text] [Related]
25. [Improvement in anti-hemophilic preparations and its problems. 7. Present status and future aspect of anti-hemophilic preparations].
Kamiya T
Rinsho Ketsueki; 1988 May; 29(5):666-70. PubMed ID: 3145998
[No Abstract] [Full Text] [Related]
26. [Circulating anticoagulants during hemophilia].
Josso F; Cosson A; Gazengel C; Allain JP
Rev Fr Transfus; 1972 Dec; 15(4):281-98. PubMed ID: 4659598
[No Abstract] [Full Text] [Related]
27. Chairman's Introductory remarks.
Shulman NR
Ann N Y Acad Sci; 1975 Jan; 240():7. PubMed ID: 1053888
[No Abstract] [Full Text] [Related]
28. Recombinant factor IX.
White GC; Beebe A; Nielsen B
Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
[TBL] [Abstract][Full Text] [Related]
29. Factor VIII, factor IX and fibrinogen content in cryoprecipitate, fresh plasma and cryoprecipitate-removed plasma.
Bejrachandra S; Chandanayingyong D; Visudhiphan S; Tumliang S; Kaewkamol K; Siribunrit U
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():162-4. PubMed ID: 7886562
[TBL] [Abstract][Full Text] [Related]
30. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
White GC; DiMichele D; Mertens K; Negrier C; Peake IR; Prowse C; Schwaab R; Yoshioka A; Ingerslev J
Thromb Haemost; 1999 Mar; 81(3):462. PubMed ID: 10102478
[No Abstract] [Full Text] [Related]
31. A standard nomenclature for factor VIII and factor IX gene mutations and associated amino acid alterations. On behalf of the ISTH SSC Subcommittee on Factor VIII and Factor IX.
Peake I; Tuddenham E
Thromb Haemost; 1994 Sep; 72(3):475-6. PubMed ID: 7855800
[No Abstract] [Full Text] [Related]
32. [Virus in hemophilia: current status and future perspectives].
Aguilar C; Félix Lucía J
Sangre (Barc); 1996 Apr; 41(2):141-5. PubMed ID: 9045355
[No Abstract] [Full Text] [Related]
33. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
Mahasandana C; Patharathienskul D; Suvatte V
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
[TBL] [Abstract][Full Text] [Related]
34. Naturally occurring anticoagulants: a case report.
Ross SA
N Z Med J; 1968 Mar; 67(430):411-3. PubMed ID: 4968117
[No Abstract] [Full Text] [Related]
35. Blood therapy: administering blood components.
Buickus BA
Am J Nurs; 1979 May; 79(5):937-41. PubMed ID: 86300
[No Abstract] [Full Text] [Related]
36. Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission.
Robertson BH; Alter MJ; Bell BP; Evatt B; McCaustland KA; Shapiro CN; Sinha SD; Souci JM
Biologicals; 1998 Jun; 26(2):95-9. PubMed ID: 9811512
[TBL] [Abstract][Full Text] [Related]
37. [Plasma and plasma fractions in the therapy of blood coagulation disorders].
Lechler E
Internist (Berl); 1974 Sep; 15(9):461-4. PubMed ID: 4609113
[No Abstract] [Full Text] [Related]
38. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
[TBL] [Abstract][Full Text] [Related]
39. Relation between hemostatic parameters and prognostic/predictive factors in breast cancer.
Yigit E; Gönüllü G; Yücel I; Turgut M; Erdem D; Cakar B
Eur J Intern Med; 2008 Dec; 19(8):602-7. PubMed ID: 19046726
[TBL] [Abstract][Full Text] [Related]
40. [Studies on the usefulness of double filtration plasmapheresis in a hemophilia A patient with anti-factor VIII antibody (inhibitor)].
Okubo S; Ikuma T; Hamaguchi Y; Yasunaga K
Rinsho Ketsueki; 1985 May; 26(5):701-8. PubMed ID: 3932716
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
